newsfilter
← Latest News
Business Wire·

Covidien Achieves CE Mark for the Nellcor™ Bedside SpO2 Patient Monitoring System, PM100N

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien (NYSE: COV) today announced CE Mark approval for its Nellcor™ Bedside SpO2 Patient Monitoring System, PM100N. The system currently is available in the European Economic Area (EEA), Australia and New Zealand. The Nellcor™ Bedside SpO2 Patient Monitoring System is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with standards for medical electrical equipment used in the home health care environment.